Acute Myeloid Leukemia: Update on Diagnosis, Therapy, and Monitoring

Dear Colleagues,

Acute myeloid leukemia (AML) is a clonal disease that occurs due to a block in the maturation of stem cells of the myeloid lineage, their enormous proliferation, as well as suppression of apoptosis. The most common cause is the activation or inactivation of certain genes, due to various cytogenetic/molecular changes, usually chromosomal translocations, deletions or some other genetic or epigenetic disorders. The incidence of AML ranges from 3.7 to 4.3 per 100,000 population per year.

Complete diagnosis of AML includes morphological/cytochemical/immunophenotypic and cytogenetic/molecular definition of the disease, according to the recommendations of the ELN working group, 2022. The most important prognostic parameter in AML is cytogenetic/molecular findings.

Intensive therapy is reserved for patients under the age of 65, without comorbidities and includes chemotherapy, allogeneic bone marrow transplantation, depending on disease markers and targeted therapy.

Due to advanced age, other comorbidities, as well as a higher frequency of unfavorable cytogenetic characteristics, elderly patients are often not suitable for intensive treatment. In them, chemotherapy is applied in reduced doses, as well as an inhibitor of the antiapoptotic bcl-2 protein along with hypomethylating agents.

Prof. Dr. Ana Vidović
Prof. Dr. Andrija Bogdanović
Dr. Nada Kraguljac
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• acute myeloblastic leukemia
• diagnosis
• prognosis
• intensive chemotherapy
• allogeneic stem cell transplantation